Pacific Bio (NASDAQ: PACB) reported Q2 EPS of ($0.16), $0.02 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $24.9 million versus the consensus estimate of $26.36 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.